Washington: American scientists are working in a new direction regarding the treatment of the Covid-19 epidemic. A team of US scientists is working on the medicinal properties of mushrooms and the treatment of corona with the help of Chinese herbs. According to Gordon Saxe, who is posted as Principal Investigator in the Director of Research Center for Interactive Health at the University of California-San Diego, the mushroom has been chosen because of its history of use for boosting immunity and having antiviral effects.
MACH-19 (Mushroom and Chinese Herb for COVID-19) is a multi-center study working in collaboration with the San Diego School of Medicine and UC Los Angeles, La Jolla Institute for Immunology.
Better results found in preclinical studies
In a pre-clinical study conducted in the year 2019, it was found that mushrooms have the ability to prevent infection with viruses, including Influenza (H1N1), Influenza A (H5N1), and Herpes. Gordon Sachs says that he thinks that medicinal mushrooms have the ability to inhibit the replication of the virus and he wants to test this theory in the Phase-2 trial against SARS Covid-19 (SARS-CoV-2).
Gordon Sachs said that mushrooms have many benefits and they have evolved with us. Just as mushrooms fall prey to bacteria, viruses, and other fungi, so are humans. Just as mushrooms fight such pests, we are sure that we will get a defense mechanism by eating them.
The medicinal properties of the mushroom are being assessed in the third ongoing trial regarding MACH-19. It is given as a capsule at the beginning of the Covid vaccination, can it increase antibodies and how the immune system responds. He said that its fourth trial launch is yet to be done.
Mushroom increases the number of antibodies
He said that the mushroom can not only increase the number of antibodies but also increase the T-cell immunity that works against virally infected cells. have been using. Let us inform you that out of 3 trials of MACH-19, 2 trials have been approved by the Food and Drug Administration (FDA). Preliminary safety data for these trials are expected by the end of this year, while the data related to its effectiveness will be ready within a year.
